Name | Number of supported studies | Average coverage | |
---|---|---|---|
plasmacytoid dendritic cell | 18 studies | 49% ± 12% | |
ciliated cell | 12 studies | 31% ± 14% | |
epithelial cell | 10 studies | 39% ± 18% | |
basal cell | 10 studies | 32% ± 14% | |
B cell | 8 studies | 22% ± 6% | |
secretory cell | 7 studies | 31% ± 15% | |
memory B cell | 6 studies | 20% ± 4% | |
oligodendrocyte precursor cell | 6 studies | 31% ± 12% | |
club cell | 5 studies | 24% ± 6% | |
naive B cell | 5 studies | 19% ± 4% | |
respiratory goblet cell | 4 studies | 23% ± 6% | |
endothelial cell | 4 studies | 22% ± 10% | |
precursor B cell | 4 studies | 25% ± 9% | |
type I pneumocyte | 4 studies | 21% ± 6% | |
luminal hormone-sensing cell of mammary gland | 4 studies | 40% ± 13% | |
squamous epithelial cell | 3 studies | 47% ± 18% | |
immature B cell | 3 studies | 27% ± 2% | |
germinal center B cell | 3 studies | 20% ± 1% | |
luminal cell of prostate epithelium | 3 studies | 37% ± 6% | |
dendritic cell | 3 studies | 23% ± 7% | |
enterocyte | 3 studies | 18% ± 2% | |
goblet cell | 3 studies | 22% ± 4% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
pancreas | 100% | 2064.47 | 328 / 328 | 99% | 54.39 | 177 / 178 |
bladder | 100% | 2120.71 | 21 / 21 | 99% | 88.66 | 500 / 504 |
thymus | 100% | 3643.06 | 653 / 653 | 99% | 35.44 | 600 / 605 |
skin | 100% | 1670.76 | 1803 / 1809 | 99% | 63.31 | 469 / 472 |
lung | 100% | 2715.00 | 577 / 578 | 99% | 60.27 | 1145 / 1155 |
brain | 99% | 1210.46 | 2617 / 2642 | 99% | 59.19 | 698 / 705 |
prostate | 98% | 3692.64 | 241 / 245 | 99% | 63.17 | 499 / 502 |
ovary | 98% | 1361.07 | 176 / 180 | 99% | 42.53 | 426 / 430 |
liver | 100% | 3376.56 | 226 / 226 | 96% | 28.01 | 390 / 406 |
breast | 95% | 2589.92 | 438 / 459 | 99% | 64.48 | 1110 / 1118 |
stomach | 96% | 2987.44 | 344 / 359 | 99% | 50.97 | 282 / 286 |
kidney | 100% | 3869.47 | 89 / 89 | 90% | 27.21 | 808 / 901 |
uterus | 86% | 774.21 | 147 / 170 | 99% | 64.06 | 454 / 459 |
intestine | 80% | 2365.68 | 776 / 966 | 99% | 59.01 | 524 / 527 |
esophagus | 78% | 1346.55 | 1132 / 1445 | 99% | 46.45 | 182 / 183 |
adrenal gland | 100% | 1960.71 | 258 / 258 | 34% | 7.56 | 78 / 230 |
lymph node | 0% | 0 | 0 / 0 | 100% | 75.62 | 29 / 29 |
spleen | 100% | 2141.10 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 48.42 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 62.30 | 1 / 1 |
eye | 0% | 0 | 0 / 0 | 99% | 45.89 | 79 / 80 |
adipose | 88% | 836.93 | 1061 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 78% | 598.82 | 1040 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 51% | 2192.87 | 474 / 929 | 0% | 0 | 0 / 0 |
heart | 34% | 220.31 | 294 / 861 | 0% | 0 | 0 / 0 |
muscle | 3% | 15.77 | 23 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0045087 | Biological process | innate immune response |
GO_0030323 | Biological process | respiratory tube development |
GO_0046330 | Biological process | positive regulation of JNK cascade |
GO_0007165 | Biological process | signal transduction |
GO_0045860 | Biological process | positive regulation of protein kinase activity |
GO_0042981 | Biological process | regulation of apoptotic process |
GO_0006915 | Biological process | apoptotic process |
GO_0043122 | Biological process | regulation of canonical NF-kappaB signal transduction |
GO_0043161 | Biological process | proteasome-mediated ubiquitin-dependent protein catabolic process |
GO_0007585 | Biological process | respiratory gaseous exchange by respiratory system |
GO_0005856 | Cellular component | cytoskeleton |
GO_0005886 | Cellular component | plasma membrane |
GO_0048471 | Cellular component | perinuclear region of cytoplasm |
GO_0098802 | Cellular component | plasma membrane signaling receptor complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0001650 | Cellular component | fibrillar center |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0005923 | Cellular component | bicellular tight junction |
GO_0005634 | Cellular component | nucleus |
GO_0031996 | Molecular function | thioesterase binding |
GO_0016740 | Molecular function | transferase activity |
GO_0019901 | Molecular function | protein kinase binding |
GO_0042802 | Molecular function | identical protein binding |
GO_0031625 | Molecular function | ubiquitin protein ligase binding |
GO_0050699 | Molecular function | WW domain binding |
GO_0008270 | Molecular function | zinc ion binding |
GO_0005164 | Molecular function | tumor necrosis factor receptor binding |
GO_0005515 | Molecular function | protein binding |
Gene name | TRAF4 |
Protein name | TNF receptor-associated factor TNF receptor-associated factor 4 (EC 2.3.2.27) (Cysteine-rich domain associated with RING and Traf domains protein 1) (Metastatic lymph node gene 62 protein) (MLN 62) (RING finger protein 83) TNF receptor associated factor 4 |
Synonyms | CART1 RNF83 MLN62 |
Description | FUNCTION: Adapter protein with E3 ligase activity that is involved in many diverse biological processes including cell proliferation, migration, differentiation, DNA repair, platelet activation or apoptosis . Promotes EGFR-mediated signaling by facilitating the dimerization of EGFR and downstream AKT activation thereby promoting cell proliferation . Ubiquitinates SMURF2 through 'Lys-48'-linked ubiquitin chain leading to SMURF2 degradation through the proteasome and subsequently osteogenic differentiation . Promotes 'Lys-63'-mediated ubiquitination of CHK1 which in turn activates cell cycle arrest and activation of DNA repair . In addition, promotes an atypical 'Lys-29'-linked ubiquitination at the C-terminal end of IRS1 which is crucial for insulin-like growth factor (IGF) signal transduction . Regulates activation of NF-kappa-B in response to signaling through Toll-like receptors. Required for normal skeleton development, and for normal development of the respiratory tract (By similarity). Required for activation of RPS6KB1 in response to TNF signaling. Modulates TRAF6 functions. Inhibits adipogenic differentiation by activating pyruvate kinase PKM activity and subsequently the beta-catenin signaling pathway . . |
Accessions | C9JJ10 ENST00000454852.6 ENST00000584944.5 K7EJG7 K7ER49 ENST00000586813.5 ENST00000473421.1 J3QR87 ENST00000478021.1 F6SA91 ENST00000262396.10 A0A0C4DFM9 ENST00000475329.5 ENST00000422344.5 ENST00000444415.7 J9JIG0 ENST00000262395.10 [Q9BUZ4-1] K7EM06 Q9BUZ4 J3QS94 |